Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Mol Sci
2018 Oct 05;1910:. doi: 10.3390/ijms19103041.
Show Gene links
Show Anatomy links
Antibacterial and Antibiofilm Activity and Mode of Action of Magainin 2 against Drug-Resistant Acinetobacter baumannii.
Kim MK
,
Kang N
,
Ko SJ
,
Park J
,
Park E
,
Shin DW
,
Kim SH
,
Lee SA
,
Lee JI
,
Lee SH
,
Ha EG
,
Jeon SH
,
Park Y
.
???displayArticle.abstract???
Antimicrobial peptides (AMPs) are promising therapeutic agents for treating antibiotic-resistant bacterial infections. Previous studies showed that magainin 2 (isolated from African clawed fogs Xenopus laevis) has antimicrobial activity against gram-positive and gram-negative bacteria. The present study was conducted to investigate the antibacterial activity of magainin 2 against Acinetobacter baumannii. Magainin 2 showed excellent antibacterial activity against A. baumannii strains and high stability at physiological salt concentrations. This peptide was not cytotoxic towards HaCaT cells and showed no hemolytic activity. Biofilm inhibition and elimination were significantly induced in all A. baumannii strains exposed to magainin 2. We confirmed the mechanism of magainin 2 on the bacterial outer and inner membranes. Collectively, these results suggest that magainin 2 is an effective antimicrobial and antibiofilm agent against A. baumannii strains.
Figure 1. Structure analysis of magainin 2. (A) Helical wheel diagram of the peptide. The projection was obtained from http://heliquest.ipmc.cnrs.fr/cgibn/ComputParam.py. Positively charged residues are represented in blue, while hydrophobic residues are shown as yellow circles. The N-terminal and C-terminal parts are represented in red letters “N” and “C”. (B) Three-dimensional structure of magainin 2.
Figure 2. Circular dichroism (CD) spectra of magainin 2. (A) The peptide was measured in TFE, which mimics the hydrophobic environment of the microbial membrane and (B) SDS, which mimics the negatively charged prokaryotic membrane environment.
Figure 3. Cytotoxicity and hemolytic activity of magainin 2. (A) Hemolytic activity of peptides against mouse red blood cells (RBCs). (B) Cytotoxicity of peptides against HaCaT cells.
Figure 4. Effect of Acinetobacter baumannii biofilm formation by magainin 2. (A) Quantitative measurements of biofilm formation using crystal violet staining. (B) Inhibitory effect of peptides on biofilm formation. Antibiotics (ciprofloxacin and gentamicin) and buforin 2 were used as controls.
Figure 5. EVOS2 images of Acinetobacter baumannii biofilm stained with SYTO9 dye (green fluorescence).
Figure 6. Biofilm reduction assay. (A) Degree of biofilm removal by magainin 2, ciprofloxacin, and gentamicin using crystal violet staining. (B) Image of removed biofilm after treatment with 256 µM of peptide and antibiotics. (C) SYTO9-stained biofilm image.
Figure 7. Magainin 2 mechanism of action. (A,B) The outer membrane permeability of magainin 2 was measured using NPN dye. (C,D) Depolarization of cytoplasmic membrane induced by magainin 2, determined using the membrane potential-sensitive fluorescent dye DisC3-5. (A,C: Acinetobacter baumannii KCTC 2508, B,D: Acinetobacter baumannii 907233).
Baker,
Anticancer efficacy of Magainin2 and analogue peptides.
1993, Pubmed,
Xenbase
Baker,
Anticancer efficacy of Magainin2 and analogue peptides.
1993,
Pubmed
,
Xenbase
Boucher,
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
2009,
Pubmed
Brogden,
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
2005,
Pubmed
Cho,
Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer.
2018,
Pubmed
Cisneros,
Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment.
2002,
Pubmed
Fair,
Antibiotics and bacterial resistance in the 21st century.
2014,
Pubmed
Fauci,
Infectious diseases: considerations for the 21st century.
2001,
Pubmed
Fernebro,
Fighting bacterial infections-future treatment options.
2011,
Pubmed
Fields,
Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.
1990,
Pubmed
Gaddy,
Regulation of Acinetobacter baumannii biofilm formation.
2009,
Pubmed
Goldman,
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis.
1997,
Pubmed
Guerrero,
Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease.
2010,
Pubmed
Hall-Stoodley,
Bacterial biofilms: from the natural environment to infectious diseases.
2004,
Pubmed
Han,
Characterization of antibiotic peptide pores using cryo-EM and comparison to neutron scattering.
2009,
Pubmed
,
Xenbase
Hoskin,
Studies on anticancer activities of antimicrobial peptides.
2008,
Pubmed
Huang,
Inhibitory effects and mechanisms of physiological conditions on the activity of enantiomeric forms of an α-helical antibacterial peptide against bacteria.
2011,
Pubmed
Jamal,
Bacterial biofilm and associated infections.
2018,
Pubmed
Jean-François,
Pore formation induced by an antimicrobial peptide: electrostatic effects.
2008,
Pubmed
Jiang,
Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides.
2008,
Pubmed
Jiménez-Guerra,
Urinary tract infection by Acinetobacter baumannii and Pseudomonas aeruginosa: evolution of antimicrobial resistance and therapeutic alternatives.
2018,
Pubmed
Khurshid,
Significance and Diagnostic Role of Antimicrobial Cathelicidins (LL-37) Peptides in Oral Health.
2017,
Pubmed
Khurshid,
Oral antimicrobial peptides: Types and role in the oral cavity.
2016,
Pubmed
Khurshid,
Histatin peptides: Pharmacological functions and their applications in dentistry.
2017,
Pubmed
Khurshid,
Human Oral Defensins Antimicrobial Peptides: A Future Promising Antimicrobial Drug.
2018,
Pubmed
Kim,
Management of meningitis due to antibiotic-resistant Acinetobacter species.
2009,
Pubmed
Kim,
Mechanisms driving the antibacterial and antibiofilm properties of Hp1404 and its analogue peptides against multidrug-resistant Pseudomonas aeruginosa.
2018,
Pubmed
Kwon,
A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
2018,
Pubmed
Ladram,
Antimicrobial peptides from frog skin: biodiversity and therapeutic promises.
2016,
Pubmed
Laxminarayan,
Antibiotic resistance-the need for global solutions.
2013,
Pubmed
Lee,
Design of novel analogue peptides with potent antibiotic activity based on the antimicrobial peptide, HP (2-20), derived from N-terminus of Helicobacter pylori ribosomal protein L1.
2002,
Pubmed
Lee,
A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice.
2014,
Pubmed
Longo,
Biofilm formation in Acinetobacter baumannii.
2014,
Pubmed
Maragakis,
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.
2008,
Pubmed
Nagant,
Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments.
2012,
Pubmed
Nguyen,
The expanding scope of antimicrobial peptide structures and their modes of action.
2011,
Pubmed
Peleg,
Acinetobacter baumannii: emergence of a successful pathogen.
2008,
Pubmed
Qi,
Relationship between Antibiotic Resistance, Biofilm Formation, and Biofilm-Specific Resistance in Acinetobacter baumannii.
2016,
Pubmed
Rao,
Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii.
2008,
Pubmed
Rasamiravaka,
Pseudomonas aeruginosa Biofilm Formation and Persistence, along with the Production of Quorum Sensing-Dependent Virulence Factors, Are Disrupted by a Triterpenoid Coumarate Ester Isolated from Dalbergia trichocarpa, a Tropical Legume.
2015,
Pubmed
Rice,
Progress and challenges in implementing the research on ESKAPE pathogens.
2010,
Pubmed
Rice,
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.
2008,
Pubmed
Roccatano,
Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure formation in peptides: a molecular dynamics study.
2002,
Pubmed
Santajit,
Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
2016,
Pubmed
Simmaco,
Novel antimicrobial peptides from skin secretion of the European frog Rana esculenta.
1993,
Pubmed
Simmaco,
Temporins, antimicrobial peptides from the European red frog Rana temporaria.
1996,
Pubmed
Tamba,
Magainin 2-induced pore formation in the lipid membranes depends on its concentration in the membrane interface.
2009,
Pubmed
,
Xenbase
Thabit,
Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.
2015,
Pubmed
Yan,
Two hits are better than one: membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin.
2013,
Pubmed
Zasloff,
Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor.
1987,
Pubmed
,
Xenbase
Zhang,
Antimicrobial peptides.
2016,
Pubmed
del Mar Tomas,
Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection.
2005,
Pubmed
